标题: CSO Andrew Vaillant博士将介绍HBsAg在功能性治疗中的关键作用 [打印本页] 作者: StephenW 时间: 2020-7-13 21:05 标题: CSO Andrew Vaillant博士将介绍HBsAg在功能性治疗中的关键作用
CSO Dr. Andrew Vaillant to present overview of critical role of HBsAg in functional cure
MONTREAL, July 13th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced that Dr. Andrew Vaillant, CSO at Replicor, will present an overview of HBsAg in chronic HBV infection as part of the Online Research Seminars 2020 series hosted by the Baruch S. Blumberg Institute on July 16th, 2020 at 11:00 a.m. EDT.
The presentation is designed with the following goals:
1. Understand the state of the art regarding particle production in HBV infection.
2. Examine the impact of approved therapies on functional cure.
3. Examine the ability of investigational therapies to target HBV subviral particles.
4. Provide an update on nucleic acid polymers, their effects and clinical impact.
